Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

N Goekbuget; W Fiedler; N Alakel; MS Topp; M Hanoun; B Steffen; R Wasch; A Viardot; K Nachtkamp; M Stelljes; H Poeck; V Vucinic; B Boll; J Beck; L Fransecky; K Wendelin; F Schneller; C Faul; VL Buecklein; L Reiser; M Bruggemann; H Serve; S Schwartz

doi:10.1182/blood-2022-158381

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

N Goekbuget, W Fiedler, N Alakel, MS Topp, M Hanoun, B Steffen, R Wasch, A Viardot, K Nachtkamp, M Stelljes, H Poeck, V Vucinic, B Boll, J Beck, L Fransecky, K Wendelin, F Schneller, C Faul, VL Buecklein, L ReiserM Bruggemann, H Serve, S Schwartz

Research output: Contribution to journal › Abstract (Journal) › peer-review

9 Citations (Web of Science)

Original language	English
Journal	BLOOD
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-158381
Publication status	Published - 2022
Event	64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - New Orleans, LA Duration: 10 Dec 2022 → 13 Dec 2022

Access to Document

10.1182/blood-2022-158381

Cite this

Goekbuget, N., Fiedler, W., Alakel, N., Topp, MS., Hanoun, M., Steffen, B., Wasch, R., Viardot, A., Nachtkamp, K., Stelljes, M., Poeck, H., Vucinic, V., Boll, B., Beck, J., Fransecky, L., Wendelin, K., Schneller, F., Faul, C., Buecklein, VL., ... Schwartz, S. (2022). Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL. BLOOD , 140. https://doi.org/10.1182/blood-2022-158381

Goekbuget, N ; Fiedler, W ; Alakel, N et al. / Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL. In: BLOOD 2022 ; Vol. 140.

@article{d1d24149c61a4e17aea0d7a6000afe9e,

title = "Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL",

author = "N Goekbuget and W Fiedler and N Alakel and MS Topp and M Hanoun and B Steffen and R Wasch and A Viardot and K Nachtkamp and M Stelljes and H Poeck and V Vucinic and B Boll and J Beck and L Fransecky and K Wendelin and F Schneller and C Faul and VL Buecklein and L Reiser and M Bruggemann and H Serve and S Schwartz",

year = "2022",

doi = "10.1182/blood-2022-158381",

language = "English",

volume = "140",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 10-12-2022 Through 13-12-2022",

}

Goekbuget, N, Fiedler, W, Alakel, N, Topp, MS, Hanoun, M, Steffen, B, Wasch, R, Viardot, A, Nachtkamp, K, Stelljes, M, Poeck, H, Vucinic, V, Boll, B, Beck, J, Fransecky, L, Wendelin, K, Schneller, F, Faul, C, Buecklein, VL, Reiser, L, Bruggemann, M, Serve, H & Schwartz, S 2022, 'Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL', BLOOD , vol. 140. https://doi.org/10.1182/blood-2022-158381

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL. / Goekbuget, N; Fiedler, W; Alakel, N et al.
In: BLOOD , Vol. 140, 2022.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

AU - Goekbuget, N

AU - Fiedler, W

AU - Alakel, N

AU - Topp, MS

AU - Hanoun, M

AU - Steffen, B

AU - Wasch, R

AU - Viardot, A

AU - Nachtkamp, K

AU - Stelljes, M

AU - Poeck, H

AU - Vucinic, V

AU - Boll, B

AU - Beck, J

AU - Fransecky, L

AU - Wendelin, K

AU - Schneller, F

AU - Faul, C

AU - Buecklein, VL

AU - Reiser, L

AU - Bruggemann, M

AU - Serve, H

AU - Schwartz, S

PY - 2022

Y1 - 2022

U2 - 10.1182/blood-2022-158381

DO - 10.1182/blood-2022-158381

M3 - Abstract (Journal)

SN - 0006-4971

VL - 140

JO - BLOOD

JF - BLOOD

T2 - 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Y2 - 10 December 2022 through 13 December 2022

ER -

Goekbuget N, Fiedler W, Alakel N, Topp MS, Hanoun M, Steffen B et al. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL. BLOOD . 2022;140. doi: 10.1182/blood-2022-158381